SELLAS Life Sciences Group, Inc. (SLS)

SELLAS Life Sciences Group, Inc. is trading at $13.13, up 0.96% on the session. The 50 day average sits at $11.12 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 58.5, which reads as strong, and MACD is bullish crossover. Volume is below average.

The nearest support is around $12.00 with resistance near $13.73, so that band frames the current range. Average daily movement is roughly $1.09, or about 8.3% of the share price, which is what any stop placement has to allow for. The overall health score of 65 out of 100 combines a trend score of 75, momentum of 83 and a risk score of 22.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.